In a single-agent phase II clinical trial, Tian et al. evaluated the relationship between DCA concentration, glutathione S-transferase zeta 1 (GSTZ1, the primary DCA metabolizer) genotype, side effects, and patient response in six patients with multiple myeloma [158]. The gene discussed is GSTZ1; the disease is plasma cell myeloma.